acoramidis
Cardiovascular system (C01)Cardiovascular system (C01) compound in Bayer | Pharmaceuticals's portfolio. Molecular target: Transthyretin.
- Target
- Transthyretin
- Mechanism
- Transthyretin stabiliser
pharma · Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Bayer | Pharmaceuticals
Bayer Australia Ltd
Bayer | Pharmaceuticals drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Berlin, DE HQ
4 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Berlin, DE
- Employees
- 4
- Programs
- 2
- Drugs
- 15
- Patents
- 1
Bayer | Pharmaceuticals pipeline
Portfolio lens on 15 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Bayer | Pharmaceuticals drug portfolio — 15 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
aflibercept
Sensory organs (S01)US regulatory status: approved. Molecular target: Placenta growth factor.
- Target
- Placenta growth factor
- Mechanism
- Placenta growth factor inhibitor
-
Development asset linked to Bayer | Pharmaceuticals in public FDA and regional records.
-
darolutamide
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Androgen receptor.
- Target
- Androgen receptor
- Mechanism
- Androgen Receptor antagonist
-
finerenone
Cardiovascular system (C09)US regulatory status: approved. Molecular target: Mineralocorticoid receptor.
- Target
- Mineralocorticoid receptor
- Mechanism
- Mineralocorticoid receptor antagonist
-
iloprost
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Prostacyclin receptor.
- Target
- Prostacyclin receptor
- Mechanism
- Prostanoid IP receptor agonist
-
interferon beta-1b
Antineoplastic and immunomodulating agents (L03)US regulatory status: approved. Molecular target: Interferon alpha/beta receptor.
- Target
- Interferon alpha/beta receptor
- Mechanism
- Interferon alpha/beta receptor agonist
-
larotrectinib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Bayer | Pharmaceuticals's portfolio. Molecular target: Neurotrophic tyrosine kinase receptor.
- Target
- Neurotrophic tyrosine kinase receptor
- Mechanism
- Neurotrophic tyrosine kinase receptor inhibitor
-
riociguat
Cardiovascular system (C02)US regulatory status: approved. Molecular target: Soluble guanylate cyclase.
- Target
- Soluble guanylate cyclase
- Mechanism
- Soluble guanylate cyclase positive allosteric modulator
-
sorafenib
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in Bayer | Pharmaceuticals's portfolio. Mechanism: Vascular endothelial growth factor receptor inhibitor.
- Mechanism
- Vascular endothelial growth factor receptor inhibitor
-
Development asset linked to Bayer | Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Bayer | Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Bayer | Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Retinoic acid receptor.
- Target
- Retinoic acid receptor
- Mechanism
- Retinoic acid receptor agonist
-
vericiguat
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Soluble guanylate cyclase.
- Target
- Soluble guanylate cyclase
- Mechanism
- Soluble guanylate cyclase activator